SIOX — Sio Gene Therapies Share News
0.000.00%
Last trade - 00:00Brief: Axovant Announces Positive SixMonth FollowUp Data From Second Cohort Of SunrisePd Phase 2 Trial Of AxoLentiPd Gene Therapy
Brief: Axovant Gene Therapies Files For Common Stock Offering Of Up To $50.0 Mln
Brief: Axovant Gene Therapies Signed A Strategic Partnership With Viralgen
Brief: Axovant Announces Q1 Loss Per Share $0.20
Brief: Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica For Manufacturing And Supply Of Axo-Lenti-Pd
Brief: Axovant Gene Therapies Reports Q4 Loss Per Share Of $0.54
Brief: Axovant Completes Enrollment Of Low-Dose Cohort In Phase 1/2 Study Of AXO-AAV-GM1, Expands Study
Brief: Axovant Enters Into Sales Agreement With SVB Leerink LLC
Brief: Axovant Announces Full Prepayment Of Outstanding Loan From Hercules Capital
Brief: Axovant Gene Therapies Gave Notice To Voluntarily Prepay Amount Equal To $16 Mln, Under Loan And Security Agreement, Dated Feb 2, 2017
Brief: Axovant Announces Partnership With Invitae To Increase Access To Genetic Testing And Accelerate Diagnoses Of Gm1 And Gm2 Gangliosidosis
Brief: Axovant Provides Business, Operations Update During Covid-19 Pandemic
Nasdaq Trade Halt Market Wide Circuit Breaker Halt: LEVEL 1 AT 08:41 AM
U.S. STOCKS ON THE MOVE-Marathon Petroleum, Tocagen, Teva Pharma, L Brands, Six Flags
Axovant Gene Therapies falls on $65 mln stock offering
Brief: Axovant Gene Therapies Announces Pricing Of $65 Million Public Offering
Brief: Axovant Gene Therapies Announces Commencement Of Public Offering
Brief: Axovant Gene Therapies Posts Q3 Loss Per Share Of $0.62
U.S. RESEARCH ROUNDUP- Capital One Financial, Extra Space Storage, ServiceNow